Swiss government recommends Covid booster from mid-October
The Swiss authorities have recommended that people aged over 16, especially the most vulnerable, get a Covid-19 booster shot to contain a new wave of infections expected this autumn and winter.
This content was published on
3 minutes
SRF/FOPH/swissinfo.ch/sb
Português
pt
Governo suíço recomenda reforço de vacina a partir de meados de outubro
After a rise in new Covid infections in June and July due to new Omicron subvariants, cases have fallen and stabilised at a “relatively low level” in Switzerland, the Federal Office of Public Health (FOPH) saidExternal link on Friday. The number of hospital admissions is also down.
“However, based on experiences so far with SARS-CoV-2, an increase in transmissions of the virus is expected from the fall [autumn] of 2022. The risk of contracting COVID-19 and the burden for the health system could therefore increase again,” it said.
The Swiss authorities therefore recommend as a priority that people aged 65 or over, and those aged 16 to 64 with an increased risk, for example anyone with a pre-existing disease or pregnant women, get a Covid booster shot this autumn. This recommendation also applies to healthcare workers.
For anyone aged 16-64 without risk factors, a booster vaccination “makes sense after individual assessment… to reduce the risk of a serious and rare infection”, FOPH said.
Young people, aged 5-15, do not need a booster jab, as Covid symptoms are generally light or non-existent, according to the authorities. Young people who have already been infected have sufficient antibodies 16 months after getting the virus. No vaccine authorisation has been issued in Switzerland for the under-fives.
The authorities recommend both mRNA Covid vaccines, such as those from Pfizer/BioNTech or Moderna, and the protein-based Nuvaxovid vaccine as boosters. New so-called bivalent mRNA vaccines, which are tailored to the BA.1 version of Omicron and the original virus first detected in China, should be preferred for booster vaccination. But it is still possible to use the current monovalent mRNA vaccine, FOPH said.
Switzerland will receive three and a half million doses of the bivalent vaccine Spikevax from Moderna by the end of September.
Covid certificates will continue to be issued to prove vaccinations, attest to infection or show negative test results. Currently, the certificate is not used in Switzerland, but may be requested by certain countries.
The booster should be given at least four months after the last vaccination or recovery. All vaccinations that meet FOPH recommendations are free of charge. The new vaccination recommendations will come into effect on October 10, 2022.
New coronavirus infections and hospital admissions continue to fall in Switzerland. A total of 14,475 new Covid cases were reported on September 6 for the previous seven-day period, down 5.4% on the previous week. There were 196 new hospital admissions and seven reported deaths.
Around 69% of the population have so far received two doses of vaccine.
Looking ahead, the FOPH said the situation “differs markedly from that of the last two winters”. Currently, 97% of the population have antibodies against SARS-CoV-2 following vaccination or recovery.
“People without risk factors are unlikely to develop severe symptoms this fall,” it said.
More
More
Coronavirus: the situation in Switzerland
This content was published on
An overview of the latest Covid-related information in the Alpine nation.
French cross-border workers in Switzerland fear “discriminatory” unemployment reform
This content was published on
In the French region around Geneva, cross-border workers are protesting proposals to cut unemployment benefits for those working in Switzerland.
Swan infected with bird flu in central Switzerland
This content was published on
Switzerland has reported its first bird flu case of the season. A swan found dead in central Switzerland tested positive for the H5N1 virus.
Swiss researchers identify gene variants linked to cancer progression
This content was published on
ETH Zurich researchers explored genetic mutations’ effects on cell function and their role in cancer development and treatment using CRISPR/Cas techniques.
Explosion at Swiss company Givaudan’s US plant leaves two dead
This content was published on
Swiss flavour and fragrance maker Givaudan reported that an explosion at its Kentucky plant resulted in two deaths and several injuries.
Swisscom’s Vodafone Italia takeover cleared by Italian telecoms authority
This content was published on
Swisscom is one step closer to its planned acquisition of Vodafone Italia, as the Italian communications regulator has approved the €8 billion deal.
Swiss parliamentary committee proposes foreign aid cuts and military funding boost
This content was published on
A committee of the Swiss House of Representatives has proposed increasing funds for the military and agriculture while reducing foreign aid and asylum.
Swiss Rolex Submariner watches reach nearly $50 billion in total market value
This content was published on
The total market value of all Rolex Submariner watches ever made is nearly $50 billion, based on newly released production data.
Swiss Jew wrongfully detained due to prosecutor’s ‘bias’
This content was published on
A Jewish Swiss man was detained after the prosecutor argued he might flee to Israel. The Federal Court said this implies bias due to his Jewish faith.
US reportedly scrutinises Russian accounts UBS took over from Credit Suisse
This content was published on
The US is investigating Russian clients acquired by UBS during its takeover of Credit Suisse, according to three sources familiar with the matter.
WTO plans to reappoint Okonjo-Iweala before Trump swears in
This content was published on
Some member states of the World Trade Organization may seek to reappoint Director-General Ngozi Okonjo-Iweala, according to a document released on Tuesday.
Health experts recommend booster jab against Covid
This content was published on
The Swiss health authorities have called on people over the age of 80 to update their vaccination against the Covid-19 virus.
Switzerland gives green light to Moderna’s Covid vaccine for 6-11 year olds
This content was published on
The Swiss medical regulator Swissmedic has approved Moderna’s Spikevax Covid-19 vaccine for use by children aged 6 to 11 years.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.